Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
Cancer Res Treat. 2022;54(1):109-117. Published online April 27, 2021
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy.
Materials and Methods Out of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments.
Results Among 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%).
Conclusion Response to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients’ preference, morbidity, and prognosis.
Citations
Citations to this article as recorded by
Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study Zachary M. Huttinger, Emile Gogineni, Sujith Baliga, Dukagjin M. Blakaj, Priyanka Bhateja, Marcelo Bonomi, Stephen Y. Kang, Matthew O. Old, Nolan B. Seim, Kyle K. VanKoevering, Amit Agrawal, Enver Ozer, James W. Rocco, Catherine T. Haring Oral Oncology.2025; 161: 107179. CrossRef
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific Ye Guo, Torahiko Nakashima, Byoung Chul Cho, Darren W.-T. Lim, Muh-Hwa Yang, Pei-Jen Lou, June Corry, Jin Ching Lin, Guo Pei Zhu, Kyung Hwan Kim, Bin Zhang, Zhiming Li, Ruey-Long Hong, Junice Yi Siu Ng, Ee Min Tan, Yan Ping Liu, Con Stylianou, Carmel Spit Oral Oncology.2024; 148: 106657. CrossRef
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for locally advanced head and neck squamous cell carcinoma Ping Han, Faya Liang, Pan Song, Taowei Wu, Yangyang Li, Ming Gao, Peiliang Lin, Jianming Fan, Xiaoming Huang Holistic Integrative Oncology.2024;[Epub] CrossRef
Clinical prognostic factors to guide treatment strategy for HPV‑positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‑world experience Hyun Bang, Hyeon-Jong Kim, Seung Lee, Hyun Shim, Jun Hwang, Woo Bae, Ik-Joo Chung, Sang-Hee Cho Oncology Letters.2024;[Epub] CrossRef
Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma Sung‐Woo Cho, Bhumsuk Keam, Keun‐Wook Lee, Ji‐Won Kim, Doo Hee Han, Hyun Jik Kim, Jeong‐Whun Kim, Dong‐Young Kim, Chae‐Seo Rhee, Yun Jung Bae, Ji‐Hoon Kim, Keun‐Yong Eom, Hong‐Gyun Wu, Yong Hwy Kim, Chae‐Yong Kim, Sun Ha Paek, Hyojin Kim, Tae‐Bin Won International Forum of Allergy & Rhinology.2024; 14(12): 1882. CrossRef
Intra-Arterial Chemotherapy for Locally Advanced Oral Cavity Cancer B. B. Vyzhigina, M. A. Kropotov, B. I. Dolgushin, D. A. Safarov, I. V. Pogrebnyakov, S. B. Alieva Journal of oncology: diagnostic radiology and radiotherapy.2024; 7(3): 62. CrossRef
Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma Francesca Huwyler, Roland Giger, Ruben Bill, Daniel Rauch, Simon Haefliger Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Response to induction chemotherapy in sinonasal malignancies: A single‐institutional experience Sarah C. Nyirjesy, Rachel Fenberg, Margaret A. Heller, Ryan T. Judd, Michael M. Li, Brandon Koch, Marcelo Bonomi, Ricardo L. Carrau, Kyle K. VanKoevering Head & Neck.2023; 45(6): 1445. CrossRef
Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives Michaela Svajdova, Pavol Dubinsky, Tomas Kazda, Branislav Jeremic Cancers.2022; 14(21): 5385. CrossRef
Purpose
This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC).
Materials and Methods
From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated.
Results
A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression-free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively.
Conclusion
After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy ofradiation dose to the tumorregression field may be feasible and need further investigation.
Citations
Citations to this article as recorded by
Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis Haiwen Li, Qibiao Wu, Haiqing Luo, Jiayuan Wu, Wenmei Su, Lili Yu Medicine.2025; 104(3): e41278. CrossRef
Recurrent Patterns in Patients With Nasopharyngeal Caricinoma and Risks Leading to Inaccurate Delineation in Marginal Failure in the Era of Intensity‐Modulated Radiotherapy Shu Zhang, Ni Zeng, Jiangping Yang, Jiaqi Han, Jinlan He, Baofeng Duan, Xiaoqiang Chen, Xiaofang Gou, Fubin Zhu, Huizhen Liu, Ming Zeng, Di Yan, Nianyong Chen Head & Neck.2024;[Epub] CrossRef
Efficacy and Failure Patterns Following Target Volume and Dose Reduction After Neoadjuvant Therapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Xiong Zhou, Zheng Wu, Zichen Qiu, Minchuan Lin, Yalan Tao, Yong Su Head & Neck.2024;[Epub] CrossRef
Post‐induction lymph node delineation in nasopharyngeal cancer: A single‐center experience Sezin Yuce Sari, Ecem Yigit, Gozde Yazici, Ibrahim Halil Gullu, Sercan Aksoy, Gokhan Ozyigit, Mustafa Cengiz Head & Neck.2023; 45(3): 612. CrossRef
Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma Qian Chen, Liangfang Shen, Shan Li European Archives of Oto-Rhino-Laryngology.2023; 280(5): 2497. CrossRef
Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation Zheng Wu, Bin Qi, Fei-Fei Lin, Lin Zhang, Qian He, Fei-Ping Li, Hui Wang, Ya-Qian Han, Wen-Jing Yin Radiotherapy and Oncology.2023; 183: 109595. CrossRef
Optimizing induction chemotherapy regimens for radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma Ying Li, Jianping Bi, Guoliang Pi, Hanping He, Yanping Li, Dandan Zheng, Zecheng Wei, Guang Han Cancer Medicine.2023; 12(8): 9449. CrossRef
Lessons and Opportunities for Biomarker-Driven Radiation Personalization in Head and Neck Cancer Elham Rahimy, Michael F. Gensheimer, Beth Beadle, Quynh-Thu Le Seminars in Radiation Oncology.2023; 33(3): 336. CrossRef
Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study Ya-Nan Jin, Zhao-Hui Ruan, Wan-Wei Cao, Lin Yang, Wei Yao, Xiao-Feng Pei, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11929. CrossRef
Failure patterns of locoregional recurrence after reducing target volumes in patients with nasopharyngeal carcinoma receiving adaptive replanning during intensity-modulated radiotherapy: a single-center experience in China Xiate Zhou, Jian Zhu, Chao Zhou, Wei Wang, Weijun Ding, Meng Chen, Kuifei Chen, Shuling Li, Xiaofeng Chen, Haihua Yang Radiation Oncology.2023;[Epub] CrossRef
Clinical target volume design of postoperative intensity-modulated radiotherapy for major salivary gland tumours according to surgical principles: an innovative method Shaowen Lyu, Zheng Wu, Dehuan Xie, Zhiqing Long, Rui Zhong, Wang Lei, Wanqin Cheng, Jiang Hu, Xuekui Liu, Chuanmiao Xie, Yong Su Journal of Cancer Research and Clinical Oncology.2022; 148(4): 921. CrossRef
Local control and failure patterns after intensity modulated radiotherapy with reduced target volume delineation after induction chemotherapy for patients with T4 nasopharyngeal carcinoma Fang-Fang Kong, Meng-Shan Ni, Rui-Ping Zhai, Hong-Mei Ying, Chao-Su Hu Translational Oncology.2022; 16: 101324. CrossRef
Tumor factors associated with in‐field failure for nasopharyngeal carcinoma after intensity‐modulated radiotherapy Xixi Liu, Bian Wu, Jing Huang, You Qin, Zhanjie Zhang, Liangliang Shi, Xiaohua Hong, Qian Ding, Gang Peng, Kunyu Yang Head & Neck.2022; 44(4): 876. CrossRef
Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma Qian Chen, Shan Li The Laryngoscope.2022; 132(12): 2379. CrossRef
Individualized clinical target volume delineation and efficacy analysis in unilateral nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT): 10-year summary De-Huan Xie, Zheng Wu, Wang-Zhong Li, Wan-Qin Cheng, Ya-Lan Tao, Lei Wang, Shao-Wen Lv, Fei-Fei Lin, Nian-Ji Cui, Chong Zhao, Jun Ma, Shao-Min Huang, Tai-Xiang Lu, Ya-Qian Han, Yong Su Journal of Cancer Research and Clinical Oncology.2022; 148(8): 1931. CrossRef
Volumetric modulated arc therapy versus tomotherapy for late T-stage nasopharyngeal carcinoma Qian Chen, Lingwei Tang, Zhe Zhu, Liangfang Shen, Shan Li Frontiers in Oncology.2022;[Epub] CrossRef
Is a high-risk clinical target volume required? Evaluation of the dosimetric feasibility based on T staging Xingxing Yuan, Chao Yan, Shiyi Peng, Zhiping Chen, Tianzhu Lu, Qiaoying Gong, Yang Qiu, Wenming Xiong, Fenghua Ao, Guoqing Li, Jingao Li, Ziwei Tu Frontiers in Oncology.2022;[Epub] CrossRef
Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He Oral Oncology.2022; 134: 106139. CrossRef
Is Surgery an Inevitable Treatment for Advanced Salivary Lymphoepithelial Carcinoma? Three Case Reports Shaowen Lv, Dehuan Xie, Zheng Wu, Lei Wang, Yong Su Ear, Nose & Throat Journal.2021; 100(9): NP402. CrossRef
The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients Shan Li, Liangfang Shen European Archives of Oto-Rhino-Laryngology.2021; 278(8): 3027. CrossRef
Extensive pelvic and abdominal lymphadenopathy with hepatosplenomegaly treated with radiotherapy—A case report Sahil Mittal, ShaikhA Hussain, RahulV. C Tiwari, AjithB Poovathingal, BPadma Priya, Rishabh Bhanot, Heena Tiwari Journal of Family Medicine and Primary Care.2020; 9(2): 1215. CrossRef
Nutritional outcomes after radiotherapy target volume reduction for nasopharyngeal cancer: a Phase III trial Li Xiang, Jin-Feng Rong, Hao-Wen Pang, Huai-Lin He, Yue Chen, Jing-Bo Wu, Yong-Sheng Wang Future Oncology.2020; 16(9): 427. CrossRef
Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors Lachlan McDowell, June Corry, Jolie Ringash, Danny Rischin Frontiers in Oncology.2020;[Epub] CrossRef
Impact of tumor volume enlargement after induction chemotherapy on subsequent radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity‐score matching analysis Shan Li, Liangfang Shen Cancer Medicine.2020; 9(23): 8832. CrossRef
Target delineation and dose prescription of adaptive replanning intensity‐modulated radiotherapy for nasopharyngeal carcinoma Dehuan Xie, Wanqin Cheng, Shaowen Lv, Rui Zhong, Lei Wang, Jiang Hu, Mingli Wang, Shaomin Huang, Yong Su, Yunfei Xia Cancer Communications.2019; 39(1): 1. CrossRef
Chemotherapy Potentially Facilitates the Occurrence of Radiation Encephalopathy in Patients With Nasopharyngeal Carcinoma Following Radiotherapy: A Multiparametric Magnetic Resonance Imaging Study Youming Zhang, Xiaoping Yi, Jianming Gao, Li Li, Lizhi Liu, Ting Qiu, Jinlei Zhang, Yuanchao Zhang, Weihua Liao Frontiers in Oncology.2019;[Epub] CrossRef
Purpose
The purpose of this study was to evaluate the long-term clinical outcome and toxicity of induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) compared with CCRT alone for the treatment of children and adolescent locoregionally advanced nasopharyngeal carcinoma (LACANPC).
Materials and Methods
A total of 194 locoregionally advanced nasopharyngeal carcinoma patients youngerthan 21 years who received CCRT with or without IC before were included in the study population. Overall survival (OS) rate, progression-free survival (PFS) rate, locoregional recurrence-free survival (LRFS) rate, and distant metastasis-free survival (DMFS) rate were assessed by the Kaplan-Meier method and a log-rank test. Treatment toxicities were clarified and compared between two groups.
Results
One hundred and thiry of 194 patients received IC+CCRT. Patients who were younger and with more advanced TNM stage were more likely to receive IC+CCRT and intensive modulated radiotherapy. The addition of IC before CCRT failed to improve survival significantly. The matched analysis identified 43 well-balanced patients in both two groups. With a median follow-up of 51.5 months, no differences were found between the IC+CCRT group and the CCRT group in 5-year OS (83.7% vs. 74.6%, p=0.153), PFS (79.2% vs. 73.4%, p=0.355), LRFS (97.7% vs. 88.2%, p=0.083), and DMFS (81.6% vs. 81.6%, p=0.860). N3 was an independent prognostic factor predicting poorer OS, PFS, and DMFS. The addition of IC was associated with increased rates of grade 3 to 4 neutropenia.
Conclusion
This study failed to demonstrate that adding IC before CCRT could provide a significant additional survival benefit for LACANPC patients. Further investigations are warranted.
Citations
Citations to this article as recorded by
Nasopharyngeal Carcinoma in Children, Current Treatment Approach Tal Ben-Ami Journal of Pediatric Hematology/Oncology.2024; 46(3): 117. CrossRef
Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study Ya-Nan Jin, Zhao-Hui Ruan, Wan-Wei Cao, Lin Yang, Wei Yao, Xiao-Feng Pei, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11929. CrossRef
Epidemiology and treatment of head and neck malignancies in the AYA generation Takahiro Asakage International Journal of Clinical Oncology.2022; 27(3): 465. CrossRef
Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020 Yu-Jing Liang, Li-Ting Liu, Yang Li, Pan Wang, Mei-Juan Luo, Dong-Xiang Wen, Qiu-Yan Chen, Hai-Qiang Mai JAMA Network Open.2022; 5(3): e220173. CrossRef
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan British Journal of Cancer.2022; 127(7): 1239. CrossRef
Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy Ziyi Zeng, Chen Chen, Lanlan Guo, Cheng Zhang, Lei Chen, Chuanping Yuan, Lixia Lu Frontiers in Oncology.2021;[Epub] CrossRef
Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study Ya-Nan Jin, Ji-Jin Yao, Ya-Fei You, Hui-Jiao Cao, Zi-Zi Li, Dan-Ling Dai, Wang-Jian Zhang, Tia Marks, Bei Zhang, Liang-Ping Xia Radiotherapy and Oncology.2021; 161: 83. CrossRef
Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period Rejin Kebudi, Sema Bay Buyukkapu, Omer Gorgun, Kübra Ozkaya, Rasim Meral, Inci Ayan, Musa Altun Pediatric Blood & Cancer.2021;[Epub] CrossRef
Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA Yu-Jing Liang, Dong-Xiang Wen, Mei-Juan Luo, Lin-Quan Tang, Shan-Shan Guo, Pan Wang, Qiu-Yan Chen, Li-Ting Liu, Hai-Qiang Mai European Journal of Cancer.2021; 159: 133. CrossRef
LHX2 Facilitates the Progression of Nasopharyngeal Carcinoma via Activation of the FGF1/FGFR Axis Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan SSRN Electronic Journal .2021;[Epub] CrossRef
Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients Naoya Murakami, Taisuke Mori, Yuko Kubo, Seiichi Yoshimoto, Kimiteru Ito, Yoshitaka Honma, Takao Ueno, Kenya Kobayashi, Hiroyuki Okamoto, Narikazu Boku, Kana Takahashi, Koji Inaba, Kae Okuma, Hiroshi Igaki, Yuko Nakayama, Jun Itami Journal of Radiation Research.2020; 61(1): 161. CrossRef
The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis Bi-Cheng Wang, Bo-Ya Xiao, Guo-He Lin, Chang Wang, Quentin Liu BMC Cancer.2020;[Epub] CrossRef
Update in pediatric nasopharyngeal undifferentiated carcinoma Line Claude, Emmanuel Jouglar, Loig Duverge, Daniel Orbach The British Journal of Radiology.2019;[Epub] CrossRef
Purpose
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLRmin). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLRmin on OS/DFS.
Results
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLRmin (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLRmin ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Conclusion
Occurrence of neutropenia, number of myelosuppression events, and high post-NLRmin during PF/TP IC-1 have prognostic value for poor survival in LANPC.
Citations
Citations to this article as recorded by
Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer Tingting Yu, Yiwei Zhang, Jiawen Li, Zhuo Li, Rui Tong Holistic Integrative Oncology.2024;[Epub] CrossRef
Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv Cancer Medicine.2023; 12(13): 14084. CrossRef
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition) Jun Wang, Baosheng Li Precision Radiation Oncology.2023; 7(3): 150. CrossRef
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition) Jun Wang, Baosheng Li Precision Radiation Oncology.2021; 5(1): 4. CrossRef
Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen BMC Cancer.2021;[Epub] CrossRef
Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma Dan Ou, Xiaoshen Wang, Mingyao Wu, Fen Xue, Yujiao Li, Chaosu Hu, Xiayun He Strahlentherapie und Onkologie.2020; 196(3): 252. CrossRef
Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound Wei Wang, Dong Luo, Junlin Chen, Jinyun Chen, Yi Xia, Wenzhi Chen, Yan Wang Bioscience Reports.2020;[Epub] CrossRef
Purpose
The role of consolidation chemoradiation (CCRT) after systemic chemotherapy in locally advanced pancreatic cancer (LAPC) is still controversial. We aim to evaluate the effectiveness of CCRT in LAPC using systematic review and meta-analysis of prospective studies.
Materials and Methods
Prospective clinical trials of LAPC receiving chemotherapy with or without subsequent CCRT were included in the analysis. We systematically searched in PubMed, MEDLINE, Embase, and Web of Science. The primary outcome of interest was 1-year survival. Secondary endpoints were median overall survival, progression-free survival, toxicity, and resection rate.
Results
Forty-one studies with 49 study arms were included with a total of 1,018 patients receiving CCRT after induction chemotherapy (ICT) and 954 patients receiving chemotherapy alone. CCRT after ICT did not improve 1-year survival significantly in LAPC patients compared with chemotherapy alone (58% vs. 52%). ICT lasted for at least 3 months revealed significantly improved survival of additional CCRT to LAPC patients compared to chemotherapy alone (65% vs. 52%). A marginal survival benefit of consolidation CCRT was noted in studies using maintenance chemotherapy (59% vs. 52%), and fluorouracil-based CCRT (64% vs. 52%), as well as in studies conducted after the 2010 (64% vs. 55%).
Conclusion
The survival benefit of ICT+CCRT over chemotherapy alone in treating LAPC was noted when ICT lasted for at least 3 months. Fluorouracil-based CCRT, and maintenance chemotherapy were associated with improved clinical outcomes.
Citations
Citations to this article as recorded by
Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better? Rita Saúde-Conde, Benjelloun El Ghali, Julie Navez, Christelle Bouchart, Jean-Luc Van Laethem Cancers.2024; 16(13): 2423. CrossRef
Issues in the 2022 revision of the Clinical Practice Guidelines for Pancreatic Cancer -Radiotherapy- Yoshinori ITO, Satoaki NAKAMURA, Takayuki OHGURI, Masanori SOMEYA, Makoto SHINOTO Suizo.2023; 38(2): 121. CrossRef
Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer? Animesh Saha, Jonathan Wadsley, Bhawna Sirohi, Rebecca Goody, Alan Anthony, Karthikeyan Perumal, Danny Ulahanan, Fiona Collinson Pancreas.2023; 52(1): e7. CrossRef
Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer Rishi Das, Madeline R. Abbott, Scott W. Hadley, Vaibhav Sahai, Filip Bednar, Joseph R. Evans, Matthew J. Schipper, Theodore S. Lawrence, Kyle C. Cuneo Advances in Radiation Oncology.2023; 8(6): 101266. CrossRef
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study Yung-Yeh Su, Yen-Feng Chiu, Chung-Pin Li, Shih-Hung Yang, Johnson Lin, Shyh-Jer Lin, Ping-Ying Chang, Nai-Jung Chiang, Yan-Shen Shan, Hui-Ju Ch’ang, Li-Tzong Chen British Journal of Cancer.2022; 126(7): 1018. CrossRef
Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy P.J. Ross, H.S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A.M. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, N.E. Wilson, D.M. Turner, D.C. James, E. Young, M.T. Harris ESMO Open.2022; 7(1): 100356. CrossRef
Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches
Current status of non-surgical treatment of locally advanced pancreatic cancer Stavros Spiliopoulos, Maria Teresa Zurlo, Annachiara Casella, Letizia Laera, Giammarco Surico, Alessia Surgo, Alba Fiorentino, Nicola de'Angelis, Roberto Calbi, Riccardo Memeo, Riccardo Inchingolo World Journal of Gastrointestinal Oncology.2021; 13(12): 2064. CrossRef
Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes Euna Cho, S M Bakhtiar Ul Islam, Fen Jiang, Ju-Eun Park, Bora Lee, Nam Deuk Kim, Tae-Ho Hwang Cancer Research and Treatment.2020; 52(1): 309. CrossRef
ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer Felipe A. Calvo, Marco Krengli, Jose M. Asencio, Javier Serrano, Philip Poortmans, Falk Roeder, Robert Krempien, Frank W. Hensley Radiotherapy and Oncology.2020; 148: 57. CrossRef
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Christelle Bouchart, Julie Navez, Jean Closset, Alain Hendlisz, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines Laura Hartmann, Philipp Schröter, Wolfram Osen, Daniel Baumann, Rienk Offringa, Mahmoud Moustafa, Rainer Will, Jürgen Debus, Stephan Brons, Stefan Rieken, Stefan B. Eichmüller Scientific Reports.2020;[Epub] CrossRef
Contemporary management of borderline resectable pancreatic ductal adenocarcinoma Kyriaki Lekka, Evanthia Tzitzi, Alexander Giakoustidis, Vassilios Papadopoulos, Dimitrios Giakoustidis Annals of Hepato-Biliary-Pancreatic Surgery.2019; 23(2): 97. CrossRef
Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer Sung J. Ma, Austin J. Iovoli, Gregory M. Hermann, Kavitha M. Prezzano, Anurag K. Singh Cancer Medicine.2019; 8(9): 4110. CrossRef
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions Maximilian Brunner, Zhiyuan Wu, Christian Krautz, Christian Pilarsky, Robert Grützmann, Georg F. Weber International Journal of Molecular Sciences.2019; 20(18): 4543. CrossRef
Jwa Hoon Kim, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Kyu-pyo Kim, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Jihun Kim, Sun-Ju Byeon, Yoon-Koo Kang
Cancer Res Treat. 2018;50(2):518-529. Published online May 24, 2017
Purpose
The purpose of this study was to evaluate the efficacy and safety of induction chemotherapy with docetaxel, capecitabine, and cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic gastric cancer (GC).
Materials and Methods
Patients with LAGC or unresectable PAN metastatic GC received six induction chemotherapy cycles (60 mg/m2 docetaxel intravenously on day 1, 937.5 mg/m2 capecitabine orally twice daily on days 1-14, 60 mg/m2 cisplatin intravenously on day 1, and 7.5 mg/kg BEV intravenously on day 1 every 3 weeks), followed by conversion surgery. The primary endpoint was R0 resection rate.
Results
Thirty-one patients with invasion to adjacent organs but without PAN metastasis (n=14, LAGC group) or with PAN metastasis regardless of invasion (n=17, PAN group) were enrolled between July 2010 and December 2014. Twenty-seven patients (87.1%) completed six chemotherapy cycles. The most common grade ≥ 3 toxicities were neutropenia (71%), neutropenia with fever/infection (22.6%/3.2%), and stomatitis (16.1%). The clinical response and R0 resection rates were 64.3% (95% confidence interval [CI], 46.6 to 82.0) and 64.5% (LAGC group, 71.4%; PAN group, 58.8%), respectively. The pathological complete regression rate was 12.9%. After a median follow-up of 44.5 months (range, 39.4 to 49.7 months), the median progression-free survival and overall survival were 13.1 months (95% CI, 8.9 to 17.3) and 38.6 months (95% CI, 22.0 to 55.1), respectively.
Conclusion
Induction chemotherapy with DXP+BEV displayed antitumor activities with encouraging R0 resection rate and manageable toxicity profiles on patients with LAGC or PAN metastatic GC.
Citations
Citations to this article as recorded by
Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer Liang Wang, Wei Li, Ya-Gang Liu, Cui Zhang, Wei-Na Gao, Li-Fei Gao, Wei long Zhong Journal of Oncology.2022; 2022: 1. CrossRef
Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study Deguo Yu, Zhenfeng Wang, Tingbang He, Lijun Yang Frontiers in Surgery.2022;[Epub] CrossRef
Research progress in targeted therapy and immunotherapy for gastric cancer Xuewei Li, Jun Xu, Jun Xie, Wenhui Yang Chinese Medical Journal.2022; 135(11): 1299. CrossRef
Novel Drug Delivery Method Targeting Para-Aortic Lymph Nodes by Retrograde Infusion of Paclitaxel into Pigs’ Thoracic Duct Akira Saito, Natsuka Kimura, Yuji Kaneda, Hideyuki Ohzawa, Hideyo Miyato, Hironori Yamaguchi, Alan Kawarai Lefor, Ryozo Nagai, Naohiro Sata, Joji Kitayama, Kenichi Aizawa Cancers.2022; 14(15): 3753. CrossRef
New therapeutic options opened by the molecular classification of gastric cancer Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu World Journal of Gastroenterology.2018; 24(18): 1942. CrossRef
Gastric cancer: Basic aspects Henrique O. Duarte, Joana Gomes, José C. Machado, Celso A. Reis Helicobacter.2018;[Epub] CrossRef
Purpose The aim of this study is to identify the prognostic factors of distant metastasis (DM) after induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer (HNC). Materials and Methods A total of 321 patients with HNC who underwent IC followed by CRT treated between January 2005 and December 2010 were analyzed retrospectively. IC consisted of three courses of docetaxel (70 mg/m2) and cisplatin (75 mg/m2) every three weeks, followed by radiotherapy of 66-70 Gy/2 Gy per fraction/5 fractions per week concurrent with weekly cisplatin (40 mg/m2). Tumor/nodal stage, primary site, tumor differentiation, lower neck node involvement (level IV, VB, and supraclavicular regions), number of concurrent chemotherapy cycles, overall duration of radiotherapy, and response to IC were assessed as potential prognostic factors influencing DM and survival outcome. Results The five-year loco-regional recurrence and DM rates were 23.6% and 18.2%. N stage, overall duration of radiotherapy, lower neck node involvement, and response to IC were significant factors for DM. With a median follow-up period of 52 months (range, 4 to 83 months), the 5-year progression-free, DM-free, and overall survival rates were 41.2%, 50.7%, and 55.1%, respectively. Lower neck node involvement (p=0.008) and poor response to IC (p < 0.001) showed an association with significantly inferior DM-free survival. Conclusion Even with the addition of IC, the DM rate and survival outcome were poor when metastatic lower neck lymph nodes were present or when patients failed to respond after receiving IC.
Citations
Citations to this article as recorded by
Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study P. Sharmila Nirojini, N.K. Bhuvaneshwari, N. Dharsshini, S. Dhivya Bharathi, K. Velavan Indian Journal of Medical and Paediatric Oncology.2024; 45(02): 134. CrossRef
An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375) Jinlong Wei, Jing Su, Jianfeng Wang, Xiaojing Jia, Qin Zhao, Weiyan Shi, Huanhuan Wang, Zhuangzhuang Zheng, Xin Jiang Head & Neck.2024; 46(4): 915. CrossRef
Current status of systemic therapy in head and neck cancer Abhenil Mittal, Atul Sharma Journal of Chemotherapy.2022; 34(1): 9. CrossRef
Risk stratification of postoperative recurrence in hypopharyngeal squamous-cell carcinoma patients with nodal metastasis Hanqing Lin, Tian Wang, Yu Heng, Xiaoke Zhu, Liang Zhou, Ming Zhang, Yong Shi, Pengyu Cao, Lei Tao Journal of Cancer Research and Clinical Oncology.2021; 147(3): 803. CrossRef
Clinical characteristics of head and neck cancers at a tertiary care hospital Sajid Durrani, Saleh Al-Dhahari, Haneen Sebeih, Tariq Wani, Khalid Al Qahatani, Humariya Heena Population Medicine.2020;[Epub] CrossRef
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy Simon Keek, Sebastian Sanduleanu, Frederik Wesseling, Reinout de Roest, Michiel van den Brekel, Martijn van der Heijden, Conchita Vens, Calareso Giuseppina, Lisa Licitra, Kathrin Scheckenbach, Marije Vergeer, C. René Leemans, Ruud H Brakenhoff, Irene Naut PLOS ONE.2020; 15(5): e0232639. CrossRef
Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience Or Dagan, Assaf Moore, Yuval Nachalon, Uri Alkan, Ameen Biadsee, Isaac Shochat, Aron Popovtzer Head & Neck.2020; 42(11): 3118. CrossRef
Meta‐analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck Kimberley L. Kiong, Nurun Nisa de Souza, Rehena Sultana, N. Gopalakrishna Iyer The Laryngoscope.2018; 128(7): 1594. CrossRef
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions R.I. Haddad, M. Posner, R. Hitt, E.E.W. Cohen, J. Schulten, J.-L. Lefebvre, J.B. Vermorken Annals of Oncology.2018; 29(5): 1130. CrossRef
Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief Andy Karabajakian, Max Gau, Thibault Reverdy, Eve-Marie Neidhardt, Jérôme Fayette Cancers.2018; 11(1): 15. CrossRef
Revisiting Induction Chemotherapy Before Radiotherapy for Head and Neck Cancer, Part I: Carcinoma of Non-Nasopharyngeal Sites Christopher H Chapman, Upendra Parvathaneni, Sue S Yom Future Oncology.2017; 13(6): 469. CrossRef
Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer Mi Joo Chung, Yeon Sil Kim, Ji Yoon Kim, Yun Hee Lee, Ji Hyun Jang, Jin Hyoung Kang, Ie Ryung Yoo, Youn Soo Lee Cancer Research and Treatment.2016; 48(4): 1167. CrossRef
The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis J.F. Carrillo, L.C. Carrillo, M.C. Ramirez-Ortega, F.J. Ochoa-Carrillo, L.F. Oñate-Ocaña European Journal of Surgical Oncology (EJSO).2016; 42(10): 1614. CrossRef
Higher positive lymph node ratio indicates poorer distant metastasis–free survival in adenoid cystic carcinoma patients with nodal involvement Zhonglong Liu, Zao Fang, Tianguo Dai, Chenping Zhang, Jian Sun, Yue He Journal of Cranio-Maxillofacial Surgery.2015; 43(6): 751. CrossRef
Gyeong Won Lee, Jung Hun Kang, Hun Gu Kim, In Gyu Hwang, Ki Shik Shim, Seok Hyun Kim, Won Sep Lee, Woon Tae Jung, Ok Jae Lee, Jung Hyeun Cho, Joung Soon Jang, Kyu Yong Chae, Jong Seok Lee
Cancer Res Treat. 2001;33(6):489-494. Published online December 31, 2001
PURPOSE The object of this study is to evaluate the efficacy and toxicity of induction chemotherapy followed by concomitant chemoradiotherapy in locoregional esophageal cancer. MATERIALS AND METHODS Between December 1992 and December 1999, 43 patients with locoregional esophageal cancer were enrolled in this phase II trial. Patients were treated with 2-cycles of induction chemotherapy followed by concomitant chemoradiotherapy. F-P chemotherapy consists of 1,000 mg/m2/Day of 5-FU as continuous infusion on day 1~5 and 80 mg/m2 of cisplatin as an intravenous bolus on day 1 and was repeated every 3~4 weeks. All patients received 60 Gy of external beam radiation concomitantly with F-P chemotherapy; intraluminal brachytherapy was added in 12 patients. A total of 4 cycles of chemotherapy were delivered. No further treatment was planned in patients who achieved complete remission after completion of the treatment. RESULTS Among the 43 patients entered, 35 patients completed the protocol. Of the 35 evaluable patients, 12 patients (34%) achieved complete response and 13 patients (37%) achieved partial response. In 26 of 33 patients, dysphagia was improved. At a median follow-up of 22 months, the 2-year and 5-year survival rates were 39% and 19%, respectively. The median survival duration of the complete responder group was 69 months (4~100 months) and the 2-year survival rate of the complete responder group was 82%.
Toxicities were tolerable, comprised of mucositis and cytopenia. CONCLUSION Induction chemotherapy followed by concurrent chemoradiotherapy in locoregional esophageal cancer is well tolerated and effective.
Citations
Citations to this article as recorded by
A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis Yang Li, Qingwu Du, Xiaoying Wei, Zhoubo Guo, Tongda Lei, Yanqi Li, Dong Han, Xiaoyue Wu, Kunning Zhang, Tian Zhang, Xi Chen, Jie Dong, Baozhong Zhang, Hui Wei, Wencheng Zhang, Qingsong Pang, Ping Wang Frontiers in Oncology.2021;[Epub] CrossRef
Salvage Esophagectomy for Locoregional Failure After Chemoradiotherapy in Patients With Advanced Esophageal Cancer Changhoon Yoo, Ji Hyun Park, Dok Hyun Yoon, Seung-Il Park, Hyeong Ryul Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho June Song, Ho-Young Song, Ji Hoon Shin, Kyung-Ja Cho, Yong Hee Kim, Sung-Bae Kim The Annals of Thoracic Surgery.2012; 94(6): 1862. CrossRef
PURPOSE We evaluated the prognostic factors, survivals and patterns of failure of the patients with locally advanced cervical cancer who received radical radiotherapy alone and induction chemotherapy followed by radiotherapy respectively. MATERIALS AND METHODS Between May 1985 to December 1992, one hundred and sixty three patients with locally advaneed cervical cancer received curative radiotherapy. Patients were divided into two groups: control group included 69 patients who received curative radiotherapy and combined group included 94 patients who received induction chemotherapy followed by curative radiotherapy. The curative radiotherapy consisted of external pelvic radiotherapy and intracavitary brachytherapy. Induction chemotherapy was delivered in VBP (vincristine, bleomycin, cisplatin) and FP (5-FU, cisplatin). Follow up period ranged from 2 months to 99 months with median of 50 months. RESULTS The overall response rate was 94.2% in the control group and 89.4% in the combined group. The response rate by control group was 66.7% for CR (complete response), 27.5% for PR (partial response), 5.8% for NR (no response). The response rate by combined group of CR, PR, NR were 64.9%, 24.5%, 10.6%, respectively. There was no difference in response for control group and combined group (p> 0.05). The 5-year overall survival had no significant difference in between control group and combined group (54.6% vs. 57.3%).
The 5-year disease free survival also had no significant difference (52.9% vs. 55.0%). In the control group, 23 patients (33.3%) had treatment failure: twelve (17.4%) at a local recurrence, 9 (13.0%) as distant metastasis, and 2 (2.9%) with both local recurrence and distant metastasis.
In the combined group, Thirty patients (31.9%) failed therapy, with local recurrence in 21 patients (22.3%), distant metastasis in 7 patients (7.5%), and both in 2 patients (2.1%). The difference between the two groups was not significant in view of patterns of failure. The major toxicities were nausea/ vomiting, leukopenia, anemia, and diarrhea. The prognostic factors affecting were hemoglobin level, KPS (karnofsky performance status), and treatment response in both group by multivariate analysis. CONCLUSION This study did not prove the efficacy of induction chemotherapy followed by radiotherapy in locally advanced cervical cancer.
Gastric cancer is the most common malignancy in Korea. Cure for patients with gastric carcinoma can be achieved only by radical surgery. From August 1988 to May 1992, 25 patients with locally advanced unresectable gastric cancer received 5-FU(Fiuorouracil) + adriamydn + mitomycin-c or 5-FU + cisplatin based induction chemotherapy before surgem. The partial response rate after me- dian 3 cycles of induction cemotherapy was 52%, stable disease 12%, progressive disease 36%. Gastric resection was performed in 18 patients(72%); 13 patients(52%) underwent radical surgery and 5 patients(20%) underwent palliative surgery. Median survival of the patients who underwent cura- tive and palliative surgery was 24. 2 and 27 months, respectively. However, median survival of the patient who didnt undergo any surgery was only 6.5 months. The difference of median survival between curative surgery and none surgery group were significant statistically(P<0.03). Side effects of induction chemotherapy were acceptable and there were no life threatening toxicities In this study, half of the patients can undergo curative surgery after induction chemotherapy. We observe the long term survival in some patients after induction chemotherapy and surgery in loco-regionally advanced gsstric cancer. This therapeutic approch for the locally advanced stomach cancer seems to be feasible. But, prospective tandomized clinical trial is warranted in the future.